DK0900085T3 - Behandling af overdreven aggression med olanzapin - Google Patents

Behandling af overdreven aggression med olanzapin

Info

Publication number
DK0900085T3
DK0900085T3 DK96943659T DK96943659T DK0900085T3 DK 0900085 T3 DK0900085 T3 DK 0900085T3 DK 96943659 T DK96943659 T DK 96943659T DK 96943659 T DK96943659 T DK 96943659T DK 0900085 T3 DK0900085 T3 DK 0900085T3
Authority
DK
Denmark
Prior art keywords
olanzapine
treatment
excessive aggression
aggression
excessive
Prior art date
Application number
DK96943659T
Other languages
Danish (da)
English (en)
Inventor
Charles M Beasley Jr
Pierre V Tran
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0900085T3 publication Critical patent/DK0900085T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Developing Agents For Electrophotography (AREA)
DK96943659T 1996-03-11 1996-12-04 Behandling af overdreven aggression med olanzapin DK0900085T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1312796P 1996-03-11 1996-03-11

Publications (1)

Publication Number Publication Date
DK0900085T3 true DK0900085T3 (da) 2006-01-30

Family

ID=21758447

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96943659T DK0900085T3 (da) 1996-03-11 1996-12-04 Behandling af overdreven aggression med olanzapin

Country Status (22)

Country Link
EP (1) EP0900085B1 (no)
JP (1) JP2000506858A (no)
KR (1) KR19990087716A (no)
CN (1) CN1124847C (no)
AT (1) ATE306269T1 (no)
AU (1) AU719517B2 (no)
BR (1) BR9612549A (no)
CA (1) CA2248753C (no)
CZ (1) CZ296579B6 (no)
DE (1) DE69635282T2 (no)
DK (1) DK0900085T3 (no)
EA (1) EA000741B1 (no)
ES (1) ES2249789T3 (no)
HU (1) HUP9903685A3 (no)
IL (1) IL126157A (no)
NO (1) NO323579B1 (no)
NZ (1) NZ325035A (no)
PL (1) PL186975B1 (no)
RO (1) RO117347B1 (no)
TR (1) TR199801799T2 (no)
UA (1) UA57727C2 (no)
WO (1) WO1997033584A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348455B1 (en) 1998-11-23 2002-02-19 Sepracor Inc. Desmetylolanzapine compositions and methods
CA2352611A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
AU757870B2 (en) * 1998-11-23 2003-03-06 Sepracor, Inc. Pharmaceutical compositions containing olanzapine-N-oxide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595535A (en) * 1983-06-06 1986-06-17 Ciba-Geigy Corporation Diazacycloalkyl-1,2,4-triazolo[2,3-c][1,3]benzodiazepines useful as neuroleptic and/or antihistaminic agents
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
DE69527442T2 (de) * 1995-05-30 2003-02-20 Lilly Co Eli Verfahren zur behandlung von wahrnehmungsstörungen

Also Published As

Publication number Publication date
AU719517B2 (en) 2000-05-11
AU1284697A (en) 1997-10-01
IL126157A (en) 2002-09-12
EA000741B1 (ru) 2000-02-28
UA57727C2 (uk) 2003-07-15
EP0900085A1 (en) 1999-03-10
IL126157A0 (en) 1999-05-09
ATE306269T1 (de) 2005-10-15
CN1213969A (zh) 1999-04-14
NZ325035A (en) 2001-06-29
RO117347B1 (ro) 2002-02-28
EA199800822A1 (ru) 1999-02-25
KR19990087716A (ko) 1999-12-27
HUP9903685A2 (hu) 2000-03-28
CA2248753C (en) 2008-11-18
CN1124847C (zh) 2003-10-22
JP2000506858A (ja) 2000-06-06
CZ296579B6 (cs) 2006-04-12
EP0900085B1 (en) 2005-10-12
PL186975B1 (pl) 2004-04-30
TR199801799T2 (xx) 1999-01-18
CZ290598A3 (cs) 1999-09-15
PL328949A1 (en) 1999-03-01
EP0900085A4 (en) 2000-12-13
CA2248753A1 (en) 1997-09-18
NO984198D0 (no) 1998-09-11
HUP9903685A3 (en) 2001-12-28
DE69635282T2 (de) 2006-04-20
BR9612549A (pt) 1999-07-20
WO1997033584A1 (en) 1997-09-18
ES2249789T3 (es) 2006-04-01
NO323579B1 (no) 2007-06-11
NO984198L (no) 1998-11-02
DE69635282D1 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
PT936908E (pt) Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela)
DK0880350T3 (da) Behandling af dissemineret sklerose
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DK0888330T3 (da) Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
NO984197D0 (no) Fremgangsmåte for behandling av autisme
EA199800819A1 (ru) Способ лечения биполярного расстройства
BR9708037A (pt) Método para o tratamento de abuso de substância
EA199800818A1 (ru) Способ лечения бессонницы
DK0984787T3 (da) Anvendelse af lavmolekylære hepariner til forebyggelse og behandling af hjerneødemer
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
UA25399A (uk) Спосіб лікуваhhя хворих гломерулоhефритом
FI103753B (fi) Menetelmä väkirehun käsittelemiseksi